📊 RNTX Key Takeaways
Is RNTX a Good Investment? Thesis Analysis
Rein Therapeutics is a pre-revenue pharmaceutical company in acute financial distress with zero revenue generation, $50.6M operating losses, and a critical liquidity crisis. With only $3.2M cash remaining and a $19.4M annual operating burn rate, the company has approximately 2 months of cash runway absent additional financing. The 0.70x current ratio indicates inability to cover short-term obligations with current assets.
Why Buy RNTX? Key Strengths
- Minimal debt burden with no long-term debt obligations
- Positive stockholders' equity of $16.9M provides some balance sheet cushion
- Early-stage biotech company likely holds intellectual property and drug pipeline assets
RNTX Investment Risks to Consider
- Zero revenue with no visible path to profitability or commercial viability
- Extreme liquidity crisis: current ratio of 0.70x indicates inability to meet short-term obligations
- Catastrophic cash burn rate of $19.4M annually with only ~2 months of runway remaining
- No insider buying activity in past 90 days signals lack of management confidence
- Imminent bankruptcy risk without immediate significant capital raise
Key Metrics to Watch
- Monthly cash burn rate and days cash on hand to bankruptcy
- Equity financing announcements and capital raising success
- Clinical trial milestones and regulatory progress on drug candidates
- Operating cash flow trends and burn rate trajectory
RNTX Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RNTX Profitability Ratios
RNTX vs Healthcare Sector
How Rein Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is RNTX Overvalued or Undervalued?
Based on fundamental analysis, Rein Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
RNTX Balance Sheet & Liquidity
RNTX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Rein Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.51 indicates the company is currently unprofitable.
RNTX Growth Metrics (YoY)
RNTX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.5M | $-0.21 |
| Q2 2025 | N/A | -$5.5M | $-0.28 |
| Q1 2025 | N/A | -$5.5M | $-0.25 |
| Q3 2024 | N/A | -$1.8M | $-0.27 |
| Q2 2024 | N/A | -$1.8M | $-0.39 |
| Q1 2024 | N/A | -$4.8M | $-0.86 |
| Q3 2023 | N/A | -$1.8M | $-0.40 |
| Q2 2023 | N/A | -$1.8M | $-0.39 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
RNTX Capital Allocation
RNTX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Rein Therapeutics, Inc. (CIK: 0001420565)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNTX
What is the AI rating for RNTX?
Rein Therapeutics, Inc. (RNTX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNTX's key strengths?
Claude: Minimal debt burden with no long-term debt obligations. Positive stockholders' equity of $16.9M provides some balance sheet cushion.
What are the risks of investing in RNTX?
Claude: Zero revenue with no visible path to profitability or commercial viability. Extreme liquidity crisis: current ratio of 0.70x indicates inability to meet short-term obligations.
What is RNTX's revenue and growth?
Rein Therapeutics, Inc. reported revenue of $0.0.
Does RNTX pay dividends?
Rein Therapeutics, Inc. does not currently pay dividends.
Where can I find RNTX SEC filings?
Official SEC filings for Rein Therapeutics, Inc. (CIK: 0001420565) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNTX's EPS?
Rein Therapeutics, Inc. has a diluted EPS of $-1.96.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNTX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rein Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNTX stock overvalued or undervalued?
Valuation metrics for RNTX: ROE of -294.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNTX stock in 2026?
Our dual AI analysis gives Rein Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNTX's free cash flow?
Rein Therapeutics, Inc.'s operating cash flow is $-19.4M, with capital expenditures of $157.0K.
How does RNTX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -294.8% (avg: 15%), current ratio 0.70 (avg: 2).